Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

J&J to Buy Aragon For at Least $650M

By Pharmaceutical Processing | June 17, 2013

Johnson & Johnson said Monday that it has agreed to buy Aragon Pharmaceuticals Inc. for at least $650 million in cash, boosting its position in prostate drug development.

The privately-held San Diego, company is focused on the development of drugs to treat hormonally-driven cancers.

Under the terms of the deal, Johnson & Johnson will make an upfront cash payment of $650 million, plus additional payments of up to $350 million if certain milestones are met. The deal is expected to close in the third quarter.

Aragon’s lead drug candidate is a second generation androgen receptor signaling inhibitor being developed for the treatment of castration-resistant prostate cancer.

Before the deal closes, Aragon will transfer all assets other than its androgen receptor antagonist program to a newly formed company to be called Seragon Pharmaceuticals, which Aragon will spin off, the companies said.

Seragon will be based in San Diego and will be financed by the current Aragon investors. It will retain members of the company’s management team including current CEO Richard Heyman, who will become the new company’s CEO.

The boards of both companies have approved the sale.

Johnson & Johnson shares rose $1.08, or 1.3 percent, to $85.99 in morning trading. That is near the upper end of its 52-week range of $65.82 to $89.99.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE